Loomis Sayles & CO L P Supernus Pharmaceuticals, Inc. Transaction History

Loomis Sayles & CO L P

$70.3 Billion
Q1 2024

A detailed history of Loomis Sayles & CO L P transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 1,597,417 shares of SUPN stock, worth $43.3 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,597,417

Previous 1,636,490 2.39%

Holding current value

$43.3 Million

Previous $47.4 Million 15.05%

% of portfolio

0.08%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $1.06 Million - $1.37 Million	-39,073 Reduced 2.39%	1,597,417 $54.5 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $2.13 Million - $2.78 Million	-93,779 Reduced 5.42%	1,636,490 $47.4 Million
Q3 2023 Nov 09, 2023	BUY	$27.57 - $32.91 $3.78 Million - $4.51 Million	136,964 Added 8.6%	1,730,269 $47.7 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $994,298 - $1.29 Million	33,243 Added 2.13%	1,593,305 $47.9 Million
Q1 2023 May 11, 2023	BUY	$34.93 - $42.03 $18,408 - $22,149	527 Added 0.03%	1,560,062 $56.5 Million

Q4 2022 Feb 10, 2023	SELL	$31.09 - $37.88 $1.3 Million - $1.58 Million	-41,768 Reduced 2.61%	1,559,535 $55.6 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $278,082 - $342,025	-9,659 Reduced 0.6%	1,601,303 $54.2 Million
Q2 2022 Aug 05, 2022	SELL	$25.33 - $34.25 $473,620 - $640,406	-18,698 Reduced 1.15%	1,610,962 $46.6 Million
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $1.18 Million - $1.37 Million	-41,554 Reduced 2.49%	1,629,660 $52.7 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $544,461 - $706,540	20,647 Added 1.25%	1,671,214 $48.7 Million
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $741,557 - $988,847	31,502 Added 1.95%	1,650,567 $44 Million
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $31.7 Million - $39.4 Million	1,186,742 Added 274.5%	1,619,065 $49.9 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $1.99 Million - $2.59 Million	82,195 Added 23.48%	432,323 $11.3 Million
Q4 2020 Feb 12, 2021	SELL	$17.7 - $25.81 $210,169 - $306,467	-11,874 Reduced 3.28%	350,128 $8.81 Million
Q3 2020 Nov 12, 2020	SELL	$20.2 - $25.05 $30,300 - $37,575	-1,500 Reduced 0.41%	362,002 $7.54 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $209,677 - $305,375	-12,269 Reduced 3.27%	363,502 $8.63 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $3.74 Million - $6.38 Million	-258,530 Reduced 40.76%	375,771 $6.76 Million
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $9.61 Million - $14 Million	-482,266 Reduced 43.19%	634,301 $15 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $2.88 Million - $3.78 Million	113,138 Added 11.28%	1,116,567 $30.7 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $17.3 Million - $22.5 Million	578,301 Added 136.03%	1,003,429 $33.2 Million
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $617,911 - $791,763	-18,856 Reduced 4.25%	425,128 $14.9 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $3.99 Million - $6.4 Million	-129,228 Reduced 22.54%	443,984 $14.7 Million
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $275,842 - $365,313	-6,460 Reduced 1.11%	573,212 $28.9 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $247,797 - $336,297	5,619 Added 0.98%	579,672 $34.7 Million
Q1 2018 May 11, 2018	SELL	$37.15 - $46.9 $755,668 - $953,992	-20,341 Reduced 3.42%	574,053 $26.3 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $1.97 Million - $2.3 Million	-54,012 Reduced 8.33%	594,394 $23.7 Million
Q3 2017 Nov 14, 2017	SELL	$36.75 - $49.65 $719,675 - $972,295	-19,583 Reduced 2.93%	648,406 $25.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	667,989	667,989 $28.8 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Account

Loomis Sayles & CO L P Supernus Pharmaceuticals, Inc. Transaction History